Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first-line sunitinib: a medical chart review across ten centers in five European countries

Angiogenesis inhibitors have become standard of care for advanced and/or metastatic renal cell carcinoma (RCC), but data on the impact of adverse events (AEs) and treatment modifications associated with these agents are limited. Medical records were abstracted at 10 tertiary oncology centers in Euro...

Descripción completa

Detalles Bibliográficos
Autores principales: Porta, Camillo, Levy, Antonin, Hawkins, Robert, Castellano, Daniel, Bellmunt, Joaquim, Nathan, Paul, McDermott, Ray, Wagstaff, John, Donnellan, Paul, McCaffrey, John, Vekeman, Francis, Neary, Maureen P, Diaz, Jose, Mehmud, Faisal, Duh, Mei Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2014
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298378/
https://www.ncbi.nlm.nih.gov/pubmed/25045157
http://dx.doi.org/10.1002/cam4.302

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4298378/
https://www.ncbi.nlm.nih.gov/pubmed/25045157
http://dx.doi.org/10.1002/cam4.302

Ejemplares similares